As Korean biotechs advance from discovery toward clinical development, the transition often exposes critical gaps in technical standards and strategic planning. This workshop will provide actionable guidance on implementing global best practices for assay design, selectivity profiling, and translational alignment, while addressing the unique challenges faced by emerging TPD companies in Asia. Attendees will gain clarity on what global partners expect, how to structure industry standard compliant data packages, and how to better transition into the clinic.

Key Takeaways:

• Exploring the PLK1 bifunctional degrader for the treatment of SCLC and other cancer types
• Discovering the potent PROTACS and degrader antibody conjugates for “undruggable” targets including KRAS G12D, colorectal and pancreatic cancers
• The discovery of clinical-stage BTK degrader, BGB-16673 and overcoming on-target resistance from BTK inhibitors